AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ Standard Acceleration ProvisionsModerate threat

Gilead Sciences (GILD) — threat to the moat

The 2036 Biktarvy date is only as strong as Gilead's position against generic makers who did not settle.

Every patent settlement of this kind carries a trapdoor. The Biktarvy agreements are "subject to standard acceleration provisions"1, which typically let the settling generic makers launch earlier if another company does.

Biktarvy exclusivity: what is settled and what is notSettled, Oct 2025Lupin, Cipla, Laurus: not before 1 April 2036Conditionstandard acceleration provisionsSeparate Feb 2026 suitagainst Cipla, over Descovy2025 sales at stake$14,334M a yearGilead Form 8-K of 6 October 2025; Form 10-K FY2025
The date is a settlement, not a verdict.

That makes the 2036 date as strong as Gilead's weakest legal position against companies that did not settle. In February 2026 Gilead sued Cipla again, this time over Descovy2. Gilead's 10-K also warns that "loss of exclusivity may be earlier under certain circumstances"3.

The stakes are large. Every year of Biktarvy exclusivity is worth roughly a year of its $14.3 billion in sales4, and generic entry in a market as price-sensitive as US HIV would move volume fast.

Gilead has fought generic challenges before and settled them. The September 2022 agreements with Lupin, Apotex, Macleods, Hetero and Cipla fixed the dates for Descovy, Vemlidy and Odefsey5, and those dates have held. That record is the best evidence that the Biktarvy settlement will also hold, though it is evidence, not proof.

The docket matters more than the sales line here. A district court ruling against Gilead on any Biktarvy patent before 2030 would put the 2036 date itself in question.

References
  1. ReportedThe Biktarvy agreements are "subject to standard acceleration provisions", which typically let the settling generic makers launch earlier if another company does.
    Gilead Sciences Form 8-K of 6 October 2025 - settlement agreements with Lupin, Cipla and Laurus Labs; no generic entry of Biktarvy expected in the United States before 1 April 2036. — October 2025 · publ. 6 October 2025 · source ↗
  2. ReportedIn February 2026 Gilead sued Cipla again, this time over Descovy.
    Gilead Sciences Form 10-K for 2025 - patents, regulatory exclusivity, expiry dates and settlements with generic manufacturers. — FY2025 · publ. 24 February 2026 · source ↗
  3. ReportedGilead's 10-K also warns that "loss of exclusivity may be earlier under certain circumstances".
    Gilead Sciences Form 10-K for 2025 - Item 1A risk factors and pricing regulation: the IRA, Medicare negotiation, Medicaid, the ACA and tariffs. — FY2025 · publ. 24 February 2026 · source ↗
  4. ReportedEvery year of Biktarvy exclusivity is worth roughly a year of its $14.3 billion in sales, and generic entry in a market as price-sensitive as US HIV would move volume fast.
    Gilead Sciences Form 10-K for 2025 - patents, regulatory exclusivity, expiry dates and settlements with generic manufacturers. — FY2025 · publ. 24 February 2026 · source ↗
  5. ReportedThe September 2022 agreements with Lupin, Apotex, Macleods, Hetero and Cipla fixed the dates for Descovy, Vemlidy and Odefsey, and those dates have held.
    Gilead Sciences Form 10-K for 2025 - patents, regulatory exclusivity, expiry dates and settlements with generic manufacturers. — FY2025 · publ. 24 February 2026 · source ↗
Sources
Generated October 4, 2026